ARHGAP29 expression may be a novel prognostic factor of cell proliferation and invasion in prostate cancer.

Shimizu K, Matsumoto H, Hirata H, Ueno K, Samoto M, Mori J, Fujii N, Kawai Y, Inoue R, Yamamoto Y, Yano S, Shimabukuro T, Furutani-Seiki M, Matsuyama H.

Oncol Rep. 2020 Dec;44(6):2735-2745. 

 

Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer.

Kawai Y, Imada K, Akamatsu S, Zhang F, Seiler R, Hayashi T, Leong J, Beraldi E, Saxena N, Kretschmer A, Oo HZ, Contreras-Sanz A, Matsuyama H, Lin D, Fazli L, Collins CC, Wyatt AW, Black PC, Gleave ME.

Mol Cancer Ther. 2020 Oct;19(10):2210-2220.

 

Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma.

Yamamoto Y, Tsunedomi R, Fujita Y, Otori T, Ohba M, Kawai Y, Hirata H, Matsumoto H, Haginaka J, Suzuki S, Dahiya R, Hamamoto Y, Matsuyama K, Hazama S, Nagano H, Matsuyama H.

Oncotarget. 2018 Mar 30;9(24):17160-17170.

 

Extracellular miR-224 as a prognostic marker for clear cell renal cell carcinoma.

Fujii N, Hirata H, Ueno K, Mori J, Oka S, Shimizu K, Kawai Y, Inoue R, Yamamoto Y, Matsumoto H, Shimabukuro T, Udoh K, Hoshii Y, Dahiya R, Matsuyama H.

Oncotarget. 2017 Nov 15;8(66):109877-109888.

 

Germline DNA copy number variations as potential prognostic markers for non-muscle invasive bladder cancer progression.

Yamamoto Y, Suehiro Y, Suzuki A, Nawata R, Kawai Y, Inoue R, Hirata H, Matsumoto H, Yamasaki T, Sasaki K, Matsuyama H.

Oncol Lett. 2017 Jul;14(1):1193-1199.

 

The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.

Nagao K, Hara T, Nishijima J, Shimizu K, Fujii N, Kobayashi K, Kawai Y, Inoue R, Yamamoto Y, Matsumoto H, Matsuyama H.

Urol Int. 2017;99(4):446-452.

 

Impact of divergent differentiation in urothelial carcinoma on oncological outcome in patients with T1 high-grade bladder cancer.

Fujii N, Hoshii Y, Hirata H, Mori J, Shimizu K, Kobayashi K, Kawai Y, Inoue R, Yamamoto Y, Matsumoto H, Nagao K, Matsuyama H.

Jpn J Clin Oncol. 2017 Jun 1;47(6):560-567.

 

BUBR1 overexpression predicts disease-specific survival after nephroureterectomy in patients with upper tract urothelial carcinoma.

Yamamoto Y, Oga A, Akao J, Misumi T, Fuji N, Kobayashi K, Kawai Y, Inoue R, Hirata H, Matsumoto H, Nagao K, Sakano S, Matsuyama H.

Jpn J Clin Oncol. 2016 Aug;46(8):754-61. doi: 10.1093/jjco/hyw060. Epub 2016 May 12.

 

Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer.

Kawai Y, Osawa T, Kobayashi K, Inoue R, Yamamoto Y, Matsumoto H, Nagao K, Hara T, Sakano S, Nagamori S, Matsuyama H.

Asian Pac J Cancer Prev. 2015;16(14):5687-90.

 

Clinical significance of ERG rearrangement subtype and its association with increased p53 expression in Japanese and German prostate cancer.

Nishijima J, Hara T, Ikemoto K, Oga A, Kobayashi K, Kawai Y, Matsumoto H, Nagao K, Sasaki K, Gkoleizakis V, Fichtner J, Matsuyama H.

Neoplasma. 2015;62(2):278-87.

 

 siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.

Yamamoto Y, Lin PJ, Beraldi E, Zhang F, Kawai Y, Leong J, Katsumi H, Fazli L, Fraser R, Cullis PR, Gleave M.

Clin Cancer Res. 2015 Nov 1;21(21):4845-55. 

 

Copy number aberrations using multicolour fluorescence in situ hybridization (FISH) for prognostication in non-muscle-invasive bladder cancer (NIMBC).

Matsuyama H, Ikemoto K, Eguchi S, Oga A, Kawauchi S, Yamamoto Y, Kawai Y, Matsumoto H, Hara T, Nagao K, Sakano S, Sasaki K.

BJU Int. 2014 Apr;113(4):662-7. doi: 10.1111/bju.12232. Epub 2013 Jul 26.

 

Centrosome amplification in bladder washing cytology specimens is a useful prognostic biomarker for non-muscle invasive bladder cancer.

Miyachika Y, Yamamoto Y, Matsumoto H, Nishijima J, Kawai Y, Nagao K, Hara T, Sakano S, Matsuyama H.

Cancer Genet. 2013 Jan-Feb;206(1-2):12-8.

 

Association of RASSF1A genotype and haplotype with the progression of clear cell renal cell carcinoma in Japanese patients.

Kawai Y, Sakano S, Okayama N, Suehiro Y, Matsuyama H, Hinoda Y.

BJU Int. 2012 Oct;110(7):1070-5.

 

Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer.

Sakano S, Hinoda Y, Sasaki M, Wada T, Matsumoto H, Eguchi S, Shinohara A, Kawai Y, Hara T, Nagao K, Hara T, Naito K, Matsuyama H.

Pharmacogenomics. 2010 Oct;11(10):1377-87.

 

Genetic alterations at 13q14 may correlate with differences in the biological behavior of prostate cancer between Japanese and Caucasian men.

Misumi T, Yamamoto Y, Murakami T, Kawai Y, Ito H, Eguchi S, Yano S, Nagao K, Hara T, Sakano S, Naito K, Sasaki K, Fuellhase C, Arenas L, Fichtner J, Matsuyama H.

Urol Int. 2010;84(4):461-6.

 

Gender-specific association of methylenetetrahydrofolate reductase genotype and haplotype with the aggressiveness and prognosis of clear cell renal cell carcinoma in Japanese patients.

Sakano S, Hinoda Y, Okayama N, Kawai Y, Ito H, Nagao K, Hara T, Matsuyama H.

BJU Int. 2010 Aug;106(3):424-30.

 

Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma.

Kawai Y, Sakano S, Suehiro Y, Okada T, Korenaga Y, Hara T, Naito K, Matsuyama H, Hinoda Y.

Ann Oncol. 2010 Aug;21(8):1612-7.

 

Preoperative erythrocyte sedimentation rate is an independent prognostic factor in Japanese patients with localized clear cell renal cell carcinoma.

Kawai Y, Matsuyama H, Korenaga Y, Misumi T, Eguchi S, Hara T, Nagao K, Ohmi C, Sakano S, Naito K.

Urol Int. 2009;83(3):306-10.

 

Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy.

Shinohara A, Sakano S, Hinoda Y, Nishijima J, Kawai Y, Misumi T, Nagao K, Hara T, Matsuyama H.

Cancer Sci. 2009 Dec;100(12):2376-82.

 

Clinical significance of lymphovascular invasion in upper urinary tract urothelial cancer.

Akao J, Matsuyama H, Yamamoto Y, Hara T, Kawai Y, Sakano S, Ohmi C, Gondo T, Naito K.

BJU Int. 2008 Aug 5;102(5):572-5.

 

Association between DNA repair gene polymorphisms and p53 alterations in Japanese patients with muscle-invasive bladder cancer.

Sakano S, Matsumoto H, Yamamoto Y, Kawai Y, Eguchi S, Ohmi C, Matsuyama H, Naito K.

Pathobiology. 2006;73(6):295-303.

 

Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas.

Kawai Y, Sakano S, Korenaga Y, Eguchi S, Naito K.

Eur Urol. 2007 Oct;52(4):1147-55.